{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:12:33Z","timestamp":1774962753572,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,7,31]],"date-time":"2007-07-31T00:00:00Z","timestamp":1185840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,7,31]],"date-time":"2007-07-31T00:00:00Z","timestamp":1185840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1038\/sj.pcan.4501002","type":"journal-article","created":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T09:17:03Z","timestamp":1185959823000},"page":"94-98","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Association between FAS polymorphism and prostate cancer development"],"prefix":"10.1038","volume":"11","author":[{"given":"L","family":"Lima","sequence":"first","affiliation":[]},{"given":"A","family":"Morais","sequence":"additional","affiliation":[]},{"given":"F","family":"Lobo","sequence":"additional","affiliation":[]},{"given":"F M","family":"Calais-da-Silva","sequence":"additional","affiliation":[]},{"given":"F E","family":"Calais-da-Silva","sequence":"additional","affiliation":[]},{"given":"R","family":"Medeiros","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2007,7,31]]},"reference":[{"key":"BF4501002_CR1","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/35077213","volume":"17","author":"G Evan","year":"2001","unstructured":"Evan G, Vousden K . Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 17: 342\u2013348.","journal-title":"Nature"},{"key":"BF4501002_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/carcin\/21.3.485","volume":"21","author":"S Lowe","year":"2000","unstructured":"Lowe S, Lin A . Apoptosis in cancer. Carcinogenesis 2000; 21: 485\u2013495.","journal-title":"Carcinogenesis"},{"key":"BF4501002_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0092-8674(91)90614-5","volume":"66","author":"N Itoh","year":"1991","unstructured":"Itoh N, Yonehara S, Sameshima M . The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233\u2013243.","journal-title":"Cell"},{"key":"BF4501002_CR4","doi-asserted-by":"crossref","first-page":"10709","DOI":"10.1016\/S0021-9258(19)50076-X","volume":"267","author":"A Oehm","year":"1992","unstructured":"Oehm A, Behrmann I, Klas C . Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor\/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992; 267: 10709\u201310715.","journal-title":"J Biol Chem"},{"key":"BF4501002_CR5","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/0092-8674(93)90326-L","volume":"75","author":"T Suda","year":"1993","unstructured":"Suda T, Takahashi T, Nagata S . Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169\u20131178.","journal-title":"Cell"},{"key":"BF4501002_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.2787530","volume":"245","author":"B Trauth","year":"1989","unstructured":"Trauth B, Klas C, Falk W . Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301\u2013305.","journal-title":"Science"},{"key":"BF4501002_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.coph.2004.03.008","volume":"4","author":"A Houston","year":"2004","unstructured":"Houston A, O\u2019Connell J . The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 2004; 4: 321\u2013326.","journal-title":"Curr Opin Pharmacol"},{"key":"BF4501002_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s001090000112","volume":"78","author":"M Muschen","year":"2000","unstructured":"Muschen M, Warskulat U, Beckmann M . Defining CD95 as a tumor suppressor gene. J Mol Med 2000; 78: 312\u2013325.","journal-title":"J Mol Med"},{"key":"BF4501002_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.canlet.2005.02.037","volume":"233","author":"B Bel Hadj Jrad","year":"2006","unstructured":"Bel Hadj Jrad B, Mahfouth W, Bouaouina N, Gabbouj S, Ahmed SB, Ltaief M et al. A polymorphism in FAS gene promoter associated with increased risk of nasopharyngeal carcinoma and correlated with anti-nuclear autoantibodies induction. Cancer Lett 2006; 233: 21\u201327.","journal-title":"Cancer Lett"},{"key":"BF4501002_CR10","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1093\/jnci\/djh289","volume":"96","author":"P Krippl","year":"2004","unstructured":"Krippl P, Langsenlehner U, Renner W, Koppel H, Samonigg H . Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004; 96: 1478\u20131479; author reply 1479.","journal-title":"J Natl Cancer Inst"},{"key":"BF4501002_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/ijc.10800","volume":"103","author":"HC Lai","year":"2003","unstructured":"Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP, Liu HS et al. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 2003; 103: 221\u2013225.","journal-title":"Int J Cancer"},{"key":"BF4501002_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/01.fpc.0000199501.54466.de","volume":"16","author":"C Li","year":"2006","unstructured":"Li C, Larson D, Zhang Z, Liu Z, Strom SS, Gershenwald JE et al. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics 2006; 16: 253\u2013263.","journal-title":"Pharmacogenet Genomics"},{"key":"BF4501002_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/01.fpc.0000194425.58511.a7","volume":"16","author":"C Li","year":"2006","unstructured":"Li C, Wu W, Liu J, Qian L, Li A, Yang K et al. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case \u2013 control analysis. Pharmacogenet Genomics 2006; 16: 245\u2013251.","journal-title":"Pharmacogenet Genomics"},{"key":"BF4501002_CR14","first-page":"4327","volume":"63","author":"K Sibley","year":"2003","unstructured":"Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003; 63: 4327\u20134330.","journal-title":"Cancer Res"},{"key":"BF4501002_CR15","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1093\/jnci\/djh187","volume":"96","author":"T Sun","year":"2004","unstructured":"Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D . Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004; 96: 1030\u20131036.","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"BF4501002_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/ijgc-00009577-200602001-00028","volume":"16","author":"M Ueda","year":"2006","unstructured":"Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H et al. Fas gene promoter \u2013670 polymorphism in gynecological cancer. Int J Gynecol Cancer 2006; 16 (Suppl 1): 179\u2013182.","journal-title":"Int J Gynecol Cancer"},{"key":"BF4501002_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0169-5002(03)00276-9","volume":"42","author":"LE Wang","year":"2003","unstructured":"Wang LE, Cheng L, Spitz MR, Wei Q . Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer 2003; 42: 1\u20138.","journal-title":"Lung Cancer"},{"key":"BF4501002_CR18","first-page":"2132","volume":"85","author":"S Yang","year":"2005","unstructured":"Yang S, Miao XP, Zhang XM, Sun T, Qu SN, Xiong P et al. Genetic polymorphisms of apoptosis-associated genes FAS and FASL and risk of colorectal cancer. Zhonghua Yi Xue Za Zhi 2005; 85: 2132\u20132135.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"BF4501002_CR19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/carcin\/bgl250","volume":"28","author":"B Zhang","year":"2007","unstructured":"Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007; 28: 1067\u20131073.","journal-title":"Carcinogenesis"},{"key":"BF4501002_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1136\/jmg.2004.030106","volume":"42","author":"X Zhang","year":"2005","unstructured":"Zhang X, Miao X, Sun T, Tan W, Qu S, Xiong P et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005; 42: 479\u2013484.","journal-title":"J Med Genet"},{"key":"BF4501002_CR21","doi-asserted-by":"publisher","first-page":"5596","DOI":"10.1158\/1078-0432.CCR-05-1739","volume":"12","author":"Z Zhang","year":"2006","unstructured":"Zhang Z, Wang LE, Sturgis EM, El-Naggar AK, Hong WK, Amos CI et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 2006; 12: 5596\u20135602.","journal-title":"Clin Cancer Res"},{"key":"BF4501002_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ygyno.2005.05.010","volume":"99","author":"HC Lai","year":"2005","unstructured":"Lai HC, Lin WY, Lin YW, Chang CC, Yu MH, Chen CC et al. Genetic polymorphisms of FAS and FASL (CD95\/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene\u2013gene interaction. Gynecol Oncol 2005; 99: 113\u2013118.","journal-title":"Gynecol Oncol"},{"key":"BF4501002_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0161-5890(97)00081-3","volume":"34","author":"QR Huang","year":"1997","unstructured":"Huang QR, Morris D, Manolios N . Identification and characterization of polymorphisms in the promoter region of the human Apo-1\/Fas (CD95) gene. Mol Immunol 1997; 34: 577\u2013582.","journal-title":"Mol Immunol"},{"key":"BF4501002_CR24","first-page":"1183","volume":"29","author":"S Kanemitsu","year":"2002","unstructured":"Kanemitsu S, Ihara K, Saifddin A, Otsuka T, Takeuchi T, Nagayama J et al. A functional polymorphism in fas (CD95\/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 2002; 29: 1183\u20131188.","journal-title":"J Rheumatol"},{"key":"BF4501002_CR25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.0.CO;2-B","volume":"85","author":"AW Hsing","year":"2000","unstructured":"Hsing AW, Tsao L, Devesa SS . International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85: 60\u201367.","journal-title":"Int J Cancer"},{"key":"BF4501002_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.suronc.2005.05.003","volume":"14","author":"SR Bott","year":"2005","unstructured":"Bott SR, Arya M, Shergill IS, Williamson M . Molecular changes in prostatic cancer. Surg Oncol 2005; 14: 91\u2013104.","journal-title":"Surg Oncol"},{"key":"BF4501002_CR27","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/00008469-200410000-00002","volume":"13","author":"R Ribeiro","year":"2004","unstructured":"Ribeiro R, Lopes C, Medeiros R . Leptin and prostate: implications for cancer prevention\u2014overview of genetics and molecular interactions. Eur J Cancer Prev 2004; 13: 359\u2013368.","journal-title":"Eur J Cancer Prev"},{"key":"BF4501002_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/sj.pcan.4500844","volume":"9","author":"R Ribeiro","year":"2006","unstructured":"Ribeiro R, Lopes C, Medeiros R . The link between obesity and prostate cancer: the leptin pathway and therapeutic perspectives. Prostate Cancer Prostatic Dis 2006; 9: 19\u201324.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BF4501002_CR29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/pros.20241","volume":"64","author":"S Costa","year":"2005","unstructured":"Costa S, Pinto D, Morais A, Vasconcelos A, Oliveira J, Lopes C et al. Acetylation genotype and the genetic susceptibility to prostate cancer in a southern European population. Prostate 2005; 64: 246\u2013252.","journal-title":"Prostate"},{"key":"BF4501002_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/00008469-200306000-00007","volume":"12","author":"PM Ferreira","year":"2003","unstructured":"Ferreira PM, Medeiros R, Vasconcelos A, Costa S, Pinto D, Morais A et al. Association between CYP2E1 polymorphisms and susceptibility to prostate cancer. Eur J Cancer Prev 2003; 12: 205\u2013211.","journal-title":"Eur J Cancer Prev"},{"key":"BF4501002_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2217\/14796694.2.2.233","volume":"2","author":"T Habuchi","year":"2006","unstructured":"Habuchi T . Common genetic polymorphisms and prognosis of sporadic cancers: prostate cancer as a model. Future Oncol 2006; 2: 233\u2013245.","journal-title":"Future Oncol"},{"key":"BF4501002_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/pros.10135","volume":"53","author":"R Medeiros","year":"2002","unstructured":"Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J et al. Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate 2002; 53: 88\u201394.","journal-title":"Prostate"},{"key":"BF4501002_CR33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/00008469-200208000-00005","volume":"11","author":"R Medeiros","year":"2002","unstructured":"Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J et al. Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev 2002; 11: 343\u2013350.","journal-title":"Eur J Cancer Prev"},{"key":"BF4501002_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s100380200060","volume":"47","author":"R Medeiros","year":"2002","unstructured":"Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J et al. The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. J Hum Genet 2002; 47: 413\u2013418.","journal-title":"J Hum Genet"},{"key":"BF4501002_CR35","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/pros.10348","volume":"58","author":"R Medeiros","year":"2004","unstructured":"Medeiros R, Vasconcelos A, Costa S, Pinto D, Ferreira P, Lobo F et al. Metabolic susceptibility genes and prostate cancer risk in a southern European population: the role of glutathione S-transferases GSTM1, GSTM3, and GSTT1 genetic polymorphisms. Prostate 2004; 58: 414\u2013420.","journal-title":"Prostate"},{"key":"BF4501002_CR36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/pros.20004","volume":"59","author":"R Ribeiro","year":"2004","unstructured":"Ribeiro R, Vasconcelos A, Costa S, Pinto D, Morais A, Oliveira J et al. Overexpressing leptin genetic polymorphism (\u20132548 G\/A) is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate 2004; 59: 268\u2013274.","journal-title":"Prostate"},{"key":"BF4501002_CR37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/path.1529","volume":"202","author":"R Medeiros","year":"2004","unstructured":"Medeiros R, Vasconcelos A, Costa S, Pinto D, Lobo F, Morais A et al. Linkage of angiotensin I-converting enzyme gene insertion\/deletion polymorphism to the progression of human prostate cancer. J Pathol 2004; 202: 330\u2013335.","journal-title":"J Pathol"},{"key":"BF4501002_CR38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0165-4608(02)00660-X","volume":"141","author":"R Medeiros","year":"2003","unstructured":"Medeiros R, Vasconcelos A, Costa S, Pinto D, Morais A, Oliveira J et al. Steroid hormone genotypes ARStuI and ER325 are linked to the progression of human prostate cancer. Cancer Genet Cytogenet 2003; 141: 91\u201396.","journal-title":"Cancer Genet Cytogenet"},{"key":"BF4501002_CR39","first-page":"3433","volume":"8","author":"RM Medeiros","year":"2002","unstructured":"Medeiros RM, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J et al. Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7. Clin Cancer Res 2002; 8: 3433\u20133437.","journal-title":"Clin Cancer Res"},{"key":"BF4501002_CR40","first-page":"23","volume":"14","author":"G Wang","year":"2004","unstructured":"Wang G, Reed E, Li QQ . Apoptosis in prostate cancer: progressive and therapeutic implications (Review). Int J Mol Med 2004; 14: 23\u201334.","journal-title":"Int J Mol Med"},{"key":"BF4501002_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/(SICI)1096-9896(199906)188:2<207::AID-PATH337>3.0.CO;2-8","volume":"188","author":"SH Lee","year":"1999","unstructured":"Lee SH, Shin MS, Lee JY, Park WS, Kim SY, Jang JJ et al. In vivo expression of soluble Fas and FAP-1: possible mechanisms of Fas resistance in human hepatoblastomas. J Pathol 1999; 188: 207\u2013212.","journal-title":"J Pathol"},{"key":"BF4501002_CR42","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/cncr.10674","volume":"95","author":"J Jiang","year":"2002","unstructured":"Jiang J, Ulbright TM, Zhang S, Eckert GJ, Kao C, Gardner TA et al. Fas and Fas ligand expression is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Cancer 2002; 95: 296\u2013300.","journal-title":"Cancer"},{"key":"BF4501002_CR43","first-page":"3595","volume":"21","author":"Y Furuya","year":"2001","unstructured":"Furuya Y, Fuse H, Masai M . Serum soluble Fas level for detection and staging of prostate cancer. Anticancer Res 2001; 21: 3595\u20133598.","journal-title":"Anticancer Res"},{"key":"BF4501002_CR44","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1507\/endocrj.50.629","volume":"50","author":"Y Furuya","year":"2003","unstructured":"Furuya Y, Nagakawa O, Fuse H . Prognostic significance of serum soluble Fas level and its change during regression and progression of advanced prostate cancer. Endocr J 2003; 50: 629\u2013633.","journal-title":"Endocr J"},{"key":"BF4501002_CR45","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.4049\/jimmunol.154.6.2706","volume":"154","author":"I Cascino","year":"1995","unstructured":"Cascino I, Fiucci G, Papoff G, Ruberti G . Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995; 154: 2706\u20132713.","journal-title":"J Immunol"},{"key":"BF4501002_CR46","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1126\/science.7510905","volume":"263","author":"J Cheng","year":"1994","unstructured":"Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759\u20131762.","journal-title":"Science"},{"key":"BF4501002_CR47","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0022-5347(01)62960-4","volume":"160","author":"Y Mizutani","year":"1998","unstructured":"Mizutani Y, Yoshida O, Bonavida B . Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J Urol 1998; 160: 571\u2013576.","journal-title":"J Urol"},{"key":"BF4501002_CR48","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1089\/108497802760804790","volume":"17","author":"Y Mizutani","year":"2002","unstructured":"Mizutani Y, Yoshida O, Ukimura O, Kawauchi A, Bonavida B, Miki T . Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. Cancer Biother Radiopharm 2002; 17: 563\u2013567.","journal-title":"Cancer Biother Radiopharm"},{"key":"BF4501002_CR49","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/cncr.21795","volume":"106","author":"RS Svatek","year":"2006","unstructured":"Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI et al. Soluble Fas\u2014a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 2006; 106: 1701\u20131707.","journal-title":"Cancer"},{"key":"BF4501002_CR50","first-page":"1183","volume":"11","author":"M Murakami","year":"2004","unstructured":"Murakami M, Sasaki T, Miyata H, Yamasaki S, Kuwahara K, Chayama K . Fas and Fas ligand: expression and soluble circulating levels in bile duct carcinoma. Oncol Rep 2004; 11: 1183\u20131186.","journal-title":"Oncol Rep"},{"key":"BF4501002_CR51","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00268-002-6378-5","volume":"27","author":"SM Sheen-Chen","year":"2003","unstructured":"Sheen-Chen SM, Chen HS, Eng HL, Chen WJ . Circulating soluble Fas in patients with breast cancer. World J Surg 2003; 27: 10\u201313.","journal-title":"World J Surg"},{"key":"BF4501002_CR52","first-page":"3529","volume":"5","author":"T Ueno","year":"1999","unstructured":"Ueno T, Toi M, Tominaga T . Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res 1999; 5: 3529\u20133533.","journal-title":"Clin Cancer Res"},{"key":"BF4501002_CR53","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1023\/A:1017908320634","volume":"131","author":"NE Kushlinskii","year":"2001","unstructured":"Kushlinskii NE, Britvin TA, Abbasova SG, Perevoshchikov AG, Prorokov VV, Kostanyan IA et al. Soluble Fas antigen in the serum of patients with colon cancer. Bull Exp Biol Med 2001; 131: 361\u2013363.","journal-title":"Bull Exp Biol Med"},{"key":"BF4501002_CR54","first-page":"473","volume":"5","author":"H Li","year":"2000","unstructured":"Li H, Liu N, Guo L, Li JW, Liu J . Frequent expression of soluble Fas and Fas ligand in Chinese stomach cancer and its preneoplastic lesions. Int J Mol Med 2000; 5: 473\u2013476.","journal-title":"Int J Mol Med"},{"key":"BF4501002_CR55","first-page":"3576","volume":"6","author":"R Konno","year":"2000","unstructured":"Konno R, Takano T, Sato S, Yajima A . Serum soluble fas level as a prognostic factor in patients with gynecological malignancies. Clin Cancer Res 2000; 6: 3576\u20133580.","journal-title":"Clin Cancer Res"},{"key":"BF4501002_CR56","first-page":"1282","volume":"7","author":"S Ugurel","year":"2001","unstructured":"Ugurel S, Rappl G, Tilgen W, Reinhold U . Increased soluble CD95 (sFas\/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 2001; 7: 1282\u20131286.","journal-title":"Clin Cancer Res"},{"key":"BF4501002_CR57","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.ajog.2005.05.082","volume":"193","author":"A Fuks","year":"2005","unstructured":"Fuks A, Parton LA, Polavarapu S, Netta D, Strassberg S, Godi I et al. Polymorphism of Fas and Fas ligand in preterm premature rupture of membranes in singleton pregnancies. Am J Obstet Gynecol 2005; 193: 1132\u20131136.","journal-title":"Am J Obstet Gynecol"},{"key":"BF4501002_CR58","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jneuroim.2003.10.002","volume":"146","author":"OH Kantarci","year":"2004","unstructured":"Kantarci OH, Hebrink DD, Achenbach SJ, Atkinson EJ, de Andrade M, McMurray CT et al. CD95 polymorphisms are associated with susceptibility to MS in women. A population-based study of CD95 and CD95L in MS. J Neuroimmunol 2004; 146: 162\u2013170.","journal-title":"J Neuroimmunol"},{"key":"BF4501002_CR59","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/ard.2003.006056","volume":"63","author":"CG Mullighan","year":"2004","unstructured":"Mullighan CG, Heatley S, Lester S, Rischmueller M, Gordon TP, Bardy PG . Fas gene promoter polymorphisms in primary Sjogren's syndrome. Ann Rheum Dis 2004; 63: 98\u2013101.","journal-title":"Ann Rheum Dis"},{"key":"BF4501002_CR60","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/sj.cdd.4400964","volume":"9","author":"M Pinti","year":"2002","unstructured":"Pinti M, Troiano L, Nasi M, Moretti L, Monterastelli E, Mazzacani A et al. Genetic polymorphisms of Fas (CD95) and FasL (CD178) in human longevity: studies on centenarians. Cell Death Differ 2002; 9: 431\u2013438.","journal-title":"Cell Death Differ"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/4501002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/4501002","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/4501002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T16:49:37Z","timestamp":1683996577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/4501002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,31]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["BF4501002"],"URL":"https:\/\/doi.org\/10.1038\/sj.pcan.4501002","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,31]]},"assertion":[{"value":"5 April 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}